Myocardial Infarction in a Patient with Hemophilia Treated with dDAVP
- 14 January 1988
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 318 (2), 121
- https://doi.org/10.1056/nejm198801143180215
Abstract
To the Editor: Desmopressin (DDAVP) is established as effective therapy to improve hemostasis in mild or moderate hemophilia and von Willebrand's disease.1 Salzman et al. have shown a significant reduction in blood loss during cardiac surgery with the use of DDAVP, but they expressed concern about the potential prothrombotic effect of the drug on graft patency.2 We report a case that supports this concern.A 79-year-old man with mild hemophilia A (factor VIIIc [factor VIII procoagulant activity], 14 IU per deciliter) was admitted for investigation of intermittent claudication. He was a smoker, with a 15-year history of angina pectoris. Angiography . . .Keywords
This publication has 9 references indexed in Scilit:
- Treatment with Desmopressin Acetate to Reduce Blood Loss after Cardiac SurgeryNew England Journal of Medicine, 1986
- Comparative Study of Intranasal, Subcutaneous and Intravenous Administration of Desamino-D-Arginine Vasopressin (DDAVP)Thrombosis and Haemostasis, 1986
- Drugs Five Years Later: DesmopressinAnnals of Internal Medicine, 1985
- Fibrinogen as a Risk Factor for Stroke and Myocardial InfarctionNew England Journal of Medicine, 1984
- Coronary artery disease in severe haemophilia.Heart, 1983
- HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDYThe Lancet, 1980
- The reduction of mortality of abdominal aortic aneurysm resectionThe American Journal of Surgery, 1977
- Rheology of bloodPhysiological Reviews, 1969